Next Article in Journal
Research Progress of Ferula ferulaeoides: A Review
Previous Article in Journal
Synthesis and Properties of 1,3-Disubstituted Ureas Containing (Adamantan-1-yl)(phenyl)methyl Fragment Based on One-Pot Direct Adamantane Moiety Inclusion
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 8
10.3390/molecules28083578
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Silver-Promoted Radical Cascade Aryldifluoromethylation/Cyclization of 2-Allyloxybenzaldehydes for the Synthesis of 3-Aryldifluoromethyl-Containing Chroman-4-one Derivatives

by
Qianqian Sun
1,
Hongxiao Li
1,
Xingyu Chen
1,
Jian Hao
1,*,
Hongmei Deng
2 and
Haizhen Jiang
1,3,*
1
Department of Chemistry, Shanghai University, Shanghai 200444, China
2
Laboratory for Microstructures, Shanghai University, Shanghai 200444, China
3
Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China
*
Authors to whom correspondence should be addressed.
Molecules 2023, 28(8), 3578; https://doi.org/10.3390/molecules28083578
Submission received: 23 March 2023 / Revised: 12 April 2023 / Accepted: 14 April 2023 / Published: 19 April 2023
(This article belongs to the Special Issue Study of Visible Light-Promoted Fluoroalkylation Reactions)
Browse Figures
Versions Notes

Abstract

:
A convenient silver-promoted radical cascade aryldifluoromethylation/cyclization of 2-allyloxybenzaldehydes has been developed. Experimental studies disclosed that the addition of aryldifluoromethyl radicals in situ produced from easily accessible gem-difluoroarylacetic acids to unactivated double bonds in 2-allyloxybenzaldehyde was an effective route to access a series of 3-aryldifluoromethyl-containing chroman-4-one derivatives in moderate to good yields under mild reaction conditions.

1. Introduction

The chroman-4-one framework belongs to the privileged class of heterocycles and acts as a major building block in many natural products, pharmaceuticals, and biologically active compounds [1,2]. In particular, the compounds with substituents at the 3-position of the chroman-4-one exhibit significant physiological and biological activities, such as GPR119 agonist (Figure 1, a) [3], anti-HIV agent (Figure 1, b) [4], and anti-tobacco mosaic virus agent (Figure 1, c) [5] etc. Thus, a number of approaches for the synthesis of 3-substituted chroman-4-one derivatives have been developed, such as transition-metal-catalyzed cross-coupling reaction [6], Stetter reaction [7], and cascade radical cyclization [8,9,10,11,12].
The introduction of difluoromethylene group into organic molecules can not only improve chemical, physical properties and the physiological activity of the parent molecule, but also affect their binding affinity, metabolic stability, lipophilicity, and membrane permeability and bioactivity, as well as modulate pharmacokinetic behavior and penetration in biological tissues [13,14,15]. Hence, gem-difluoromethylene group (CF2) is regarded as a valuable fluorinated moiety that is extensively present in pharmaceuticals, biologically active compounds, and material molecules [16,17]. Therefore, the development of effective and general methodologies for the selective incorporation of a difluoromethylene group has become one of the hotspots in the field of organic chemistry. Traditional methods for the synthesis of the difluoromethylene-containing compounds include the direct deoxyfluorination of the carbonyl group in corresponding aldehydes or ketones by using bis(2-methoxyethyl)aminosulfur trifluoride or DAST ((C2H5)2NSF3) [18,19,20,21] and the conversion of building blocks containing difluoromethylene under specific conditions. For example, visible light-promoted the difluoromethylenation of C–H bonds under xanthone catalyzed conditions [22,23,24], and transition-metal-catalyzed (Pd- or Ni-) difluoromethylenation can be achieved applying chlorodifluoromethane [25], and so on. However, some existing methods suffer from either functional group incompatibility or the use of toxic and explosive reagents [26,27,28]. Therefore, it remains highly desired to develop practical and mild synthetic methods by using stability and easily available substrates containing-difluoromethylene building blocks, such as α,α-difluoroarylacetic acids [29,30,31,32].
Radical cascade fluoroalkylation/cyclization of alkenes has been proved to be one of the effective methods to obtain fluoroalkyl-containing heterocycle products due to the advantages that it avoids the separation and purification of intermediates [33] and realizes the introduction a fluoroalkyl group while constructing the diversity and complexity of heterocyclic skeletons. However, some fluoroalkyl radicals, such as CF3 radical, CF2H, and CnF2n+1 radical, are electron-deficient σ-radicals and thus prone to add to electron-rich alkenes. Due to electronically unfavorable conditions, it is difficult to realize the free radical cascade fluoroalkylation/cyclization of unactivated or electron-deficient alkenes. Therefore, there are only few reports on the cascade difluoromethylenation/cyclization regarding the synthesis of 3-difluoromethylene-containing chroman-4-one derivatives through the addition difluoromethyl radicals to unactivated alkenes in 2-allyloxybenzaldehydes. The reported methods include that of Zhu’s group, which developed a visible light photocatalytic aryldifluoromethylation/cyclization of alkenes using α,α-difluoroarylacetic acids (Scheme 1a) [34], and Zhou’s group and Ma’s group, which described radical cascade cyclization of alkene aldehydes using a 1-bromo-2-difluoro-containing building block (Scheme 1b) [35,36] under the visible-light photoredox catalysis conditions. Therefore, it is highly desirable to develop new, convenient methods for the synthesis of 3-difluoromethylene-containing chroman-4-one derivatives, to avoid using a relatively expensive photocatalyst in the mild reaction. Our previous research on the decarboxylation of gem-difluoroarylacetic acids under silver-catalyzed condition revealed that aryldifluoromethyl radicals have a slightly electron-rich property relative to the CF3 radical and could react with the electron-deficient activated double bond in allyl sulfones [37]. Herein, we further tried to use aryldifluoromethyl radicals from the decarboxylation of gem-difluoroarylacetic acids under the promotion of the catalytic amount of silver to explore the cascade aryldifluoromethylation/cyclization reaction with unactivated double bonds in 2-allyloxybenzaldehydes to synthesize 3-aryldifluoromethyl-containing chroman-4-one derivatives (Scheme 1c).

2. Results and Discussion

Our previous research found that the system of silver salts and persulfate salts was effective in the decarboxylation of difluoroarylacetic acids in cross-coupling reactions with allyl sulfones [37]. Therefore, 4-methyl difluorophenylacetic acid 2a and 2-(allyloxy)benzaldehyde 1a which included unactivated double bonds were chosen as model substrates to participate in the reaction in the presence of AgNO3 (20 mol%) and K2S2O8 (2 equiv.) in CH3CN/H2O (v/v = 1:1) at 80 °C under a N2 atmosphere, replacing visible light redox catalytic conditions [34]. To our delight, 3-(4-CH3)phenyldifluoromethyl-containing chroman-4-one product 3aa was observed in 56% 19F NMR yield (Table 1, entry 1). Encouraged by the result, we try to optimize the reaction conditions. When solvent was shifted from CH3CN/H2O to EtOH/H2O or DMSO/H2O, the reaction gave the desired product in lower yields (Entries 2 and 3). The product 3aa was also produced when the solvent was pure H2O, but the reaction efficiency was reduced (Entry 4). When the solvent was DMSO, the reaction could also produce the product in 32% yield (Entry 22). However, the desired product was obtained if the reaction was carried out in CH3CN (Entry 5). Upon further screening of solvents, it was found that the reaction provided the highest yield (73%) in the solvent CH3CN/H2O (v/v = 1:3) when 2 equivalents of K2S2O8 were used as oxidant (Entry 6). Other oxidants, including Na2S2O8 and (NH4)2S2O8, were also effective (Entries 7 and 8). In contrast, selectfluor failed to carry out this transformation (Entry 9). Additionally, when changing the amount of oxidant K2S2O8 from 2 into 1.75 or 2.25 equiv., the reaction efficiency was slightly reduced (Entry 6 vs 17 and 18). Moreover, oxidant K2S2O8 was actually required to bring about the cascade aryldifluoromethylation/cyclization (Entry 11). We also further evaluated the effect of the amount of AgNO3 on the reaction. AgNO3 could promote the reaction, but it was not necessary (Entry 10). A higher catalyst loading of AgNO3 did not lead to a higher reaction efficiency, and 10 mol% of AgNO3 as promoter resulted in 63% yield of 3aa (Entries 12 and 13). The other Ag (I) sources, such as AgOAc, Ag2O, or Ag2CO3, could also be used as the promoters, but they were less effective (Entries 19–21). Adjusting the ratio of 1a and 2a, it was found that 3aa was provided in the highest yield when the ratio of 1a and 2a was 1:1.5 (Entries 6, 14–16) at 80 °C for 4 h (Supplementary Materials).
Having established the optimal experimental conditions, we explored the scope and limitation of this cascade aryldifluoromethylation/cyclization by the reaction of α,α-difluoroarylacetic acids and 2-allyloxybenzaldehydes. We first explored the scope with respect to the α,α-difluoroarylacetic acids 2, as shown in Table 2. Difluoroarylacetic acids (2a–2h) bearing an electron-donating group, such as CH3, OCH3 etc., at different positions of benzene ring produced the desired product in moderate to excellent yields (3aa–3ah). When 2,2-difluoro-2-phenylacetic acid 2i was used, the reaction gave the desired product 3ai in 50% yield. The sterically hindered 2,2-difluoro-2-mesitylacetic acid 2h was also a compatible substrate in the cascade aryldifluoromethylation/cyclization leading to 3ah in 55% yield. Additionally, the α,α-difluoroarylacetic acids with different halogen groups at position-4 of the benzene ring could offer the desired products in 32 to 60% yields (3ak–am and 3ao), and the halogen groups were well tolerated. However, no desired product 3ap was obtained when the para-substituent of benzene ring in the α,α-difluoroarylacetic acid is strong electron-withdrawing nitro group. Difluoroarylacetic acids bearing a strong electron-withdrawing group, such as CN or CF3 at benzene ring, also made it difficult to provide the desired product. The results showed that the substituents on the benzene ring of α,α-difluoroarylacetic acid have a great influence on the reaction activity. This could be attributed to the fact that the electron-donating group substituted aryldifluoromethyl radicals produced in situ under silver-promoted condition demonstrated greater electron-rich property than that of non-substituted or strong electron-withdrawing group substituted phenyldifluoromethyl radical. Thus, the electron-richer aryldifluoromethyl radicals were capable of facilitating addition to unactivated double bonds in 2-allyloxybenzaldehyde. To further investigate the reaction scope, 2,2-difluoro-2-((4-methoxyphenyl)thio)acetic acid 2q was also employed as substrate, and an unexpected regio-selective product, 3aq′, was achieved in 29% yield besides the desired product 3aq in 30% yield. The structure of 3aq′ was further characterized by X-ray single crystal diffraction analysis (Figure 2) and the NMR and HR-MS etc. Additionally, when aliphatic 2,2-difluorobutanoic acid (2r) was employed in this transformation, the reaction also gave the desired product 3ar in 13% yield.
The generality of this cascade aryldifluoromethylation/cyclization toward different 2-allyloxybenzaldehydes was also explored. As shown in Table 3, a variety of 2-allyloxybenzaldehydes 1 were employed to react with 2,2-difluoro-2-(4-methoxyphenyl)acetic acid (2b). This method successfully gave the corresponding products 3 in moderate to good yields. The substrates 1b–d bearing electron-donating groups reacted smoothly, delivering the corresponding chroman-4-one derivatives 3bb–3db in moderate yields (35–50%). Unexpectedly, the reaction of the di-t-Bu-substituted 2-allyloxybenzaldehyde (1e) provided the corresponding product 3eb in trace amount in the aqueous CH3CN solution (CH3CN:H2O = 1:3) under standard conditions, while it delivered 3eb in 45% yield in the DMSO. The substrates monosubstituted by different halogens at different positions of the benzene ring in 2-allyloxybenzaldehydes (1f–1k) gave the desired product in moderate yields as well. Additionally, halogen functional groups were well tolerated in this protocol. The di-bromo-substituted substrate 1m was not a good substrate for this transformation. However, the cascade aryldifluoromethylation/cyclization of 2-((2-methylallyl)oxy) benzaldehyde 1m could afford the product 3mb in 41% in DMSO. Notably, the reaction of 2-allylbenzaldehyde 1n with 2,2-difluoro-2-(4-methylphenyl)acetic acid (2a) could also deliver the corresponding product 3na in 37% yield.
To gain more insight into the reaction mechanism and identify whether a radical pathway is involved in the silver promoted cascade aryldifluoromethylation/cyclization or not, some control experiments were carried out. When 1.0 or 1.5 equiv. of radical scavenger TEMPO were added into the reaction system of 4-methyl difluorophenylacetic acid (2a) and 2-allyloxybenzaldehyde 1a under the standard conditions, the reaction provided neither the desired product 3aa nor adduct of TEMPO with phenyldifluoromethyl radical based on 19F NMR analysis. Additionally, the conversion of 2a was completely inhibited under the standard conditions because 2a almost totally remained in the above reaction system by 19F NMR monitoring (Scheme 2a). We deduced from the results that the reaction may undergo a radical process. To further capture the phenyl difluoromethyl radical to verify this speculation, the reaction of only 4-methyl difluorophenylacetic acid (2a) used as substrate under the standard conditions in the absence of 2-allyloxybenzaldehyde 1a was performed (Scheme 2b). The phenyl difluoromethyl radical self-coupling product 4 was obtained in 16% isolated yield. Thus, it was indicated that the phenyl difluoromethyl radical as intermediate could be involved in the reaction process (Scheme 2).
On the basis of the above-mentioned results and previous reports [35,37,38,39,40,41,42], a possible mechanism for the reaction is depicted in Scheme 3. First, α,α-difluorophenylacetic acid 2 undergoes an oxidative decarboxylation process under the promotion of Ag(I) to give the corresponding phenyldifluoromethyl radical I [43]. Then, the addition of I to the unactivated C=C double bond of 2-allyloxybenzaldehyde 1a affords an alkyl radical II. The alkyl radical intermediate II attacking the C-O double bond led to an alkoxy radical intermediate IIl, realizing an intramolecular cyclization. Afterward, a formal 1,2-hydrogen atom transfer produces the α-hydroxy carbon-centered radical IV. Subsequently, radical IV is oxidized to give the carbocation intermediate V [43]. At last, the proton transfer of intermediate V leads to the final product 3a. The product 3aq’ could be formed by the cyclization of the alkyl radical intermediate II’ arising from a process similar to that of radical intermediate II to the benzene ring of 2q instead of attacking the C-O double bond.

3. Conclusions

In conclusion, we established a facile radical cascade aryldifluoromethylation/cyclization method to synthesize a series of 3-aryldifluoromethyl-containing chroman-4-one derivatives in moderate to good yields. These reactions involved the addition of aryldifluoromethyl radicals in situ produced from easily accessible gem-difluoroarylacetic acids to unactivated double bonds in 2-allyloxybenzaldehydes under silver-promoted conditions. This benign protocol replaces the use of expensive photocatalysts in visible light redox catalytic conditions and provides a new perspective to construct pharmaceutically valuable, 3-difluoromethylene-containing chroman-4-one derivatives.

4. Materials and Methods

General Procedure for the Synthesis of Compounds 3

2-Allyloxyarylaldehyde 1 (0.20 mmol), K2S2O8 (2.0 equiv, 0.40 mmol), AgNO3 (20 mol%, 0.04 mmol) and α,α-difluoroarylacetic acid 2 (1.5 equiv, 0.30 mmol) were placed in a 10-mL round-bottom flask. Solvent CH3CN/H2O (v/v = 1:3, 2.0 mL) were then added under nitrogen atmosphere. The solution was stirred at 80 °C for 4 h. The resulting mixture was cooled down to room temperature and extracted with EA (5 mL × 4). The combined organic phase was dried over anhydrous Na2SO4. After the removal of solvent under reduced pressure, the crude product was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to afford pure 3-difluoromethylene-containing chroman-4-one 3.
3-(2,2-Difluoro-2-(m-tolyl)ethyl)chroman-4-one (3ae), 35.1 mg, 58% yield, light yellow solid; mp 67.3–67.6 oC; 1H NMR (500 MHz, CDCl3) δ 7.89 (dd, J = 7.9, 1.7 Hz, 1H), 7.47 (ddd, J = 8.5, 7.2, 1.8 Hz, 1H), 7.36–7.30 (m, 3H), 7.25 (s, 1H), 7.01 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 9.0 Hz, 1H), 4.76 (dd, J = 11.4, 5.1 Hz, 1H), 4.26 (t, J = 11.7 Hz, 1H), 3.24–2.96 (m, 2H), 2.40 (s, 3H), 2.19–1.93 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −89.87 (ddd, J = 245.2, 24.6, 8.1 Hz), −97.24 (ddd, J = 245.1, 22.3, 16.2 Hz); 13C NMR (125 MHz, CDCl3) δ 192.1, 161.6, 138.5, 136.5 (t, 2JC-F = 26.0 Hz), 136.0, 130.9, 128.6, 127.5, 125.5 (t, 3JC-F = 6.1 Hz), 122.8 (t, 1JC-F = 243.4 Hz), 122.0 (t, 3JC-F = 6.2 Hz), 121.5, 120.4, 117.8, 70.5, 41.3, 34.3 (t, 2JC-F = 28.1 Hz), 21.5; IR (KBr): 3065, 2924, 1687, 1606, 1460, 1369, 1149, 1077, 764, 702, 665; HRMS (ESI) calcd. for C18H16F2O2 [M + H]+ 303.1197, found: 303.1193.
3-(2-(3,4-Dimethylphenyl)-2,2-difluoroethyl)chroman-4-one (3ag), 58.2 mg, 92% yield, light yellow solid; mp 84.5–84.9 °C; 1H NMR (500 MHz, CDCl3) δ 7.89 (dd, J = 7.9, 1.7 Hz, 1H), 7.47 (ddd, J = 8.8, 7.2, 1.8 Hz, 1H), 7.31 (s, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 7.8 Hz, 1H), 7.01 (ddd, J = 8.0, 7.3, 1.0 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.75 (dd, J = 11.5, 5.1 Hz, 1H), 4.25 (t, J = 11.7 Hz, 1H), 3.27–2.89 (m, 2H), 2.31 (s, 3H), 2.29 (s, 3H), 2.14–1.99 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −88.88 (ddd, J = 245.1, 23.9, 8.1 Hz), −96.66 (dt, J = 245.1, 19.0 Hz); 13C NMR (125 MHz, CDCl3) δ 192.2, 161.7, 138.8, 137.1, 136.0, 134.0 (t, 2JC-F = 26.2 Hz), 129.8, 127.5, 126.0 (t, 3JC-F = 6.0 Hz), 122.9 (t, 1J C-F = 242.8 Hz), 122.3 (t, 3JC-F = 6.2 Hz), 121.5, 120.4, 117.8, 70.6, 41.3, 35.3 (t, 2JC-F = 28.6 Hz), 19.9, 19.6; IR (KBr): 3051, 2925, 1688, 1607, 1467, 1393, 1138, 1028, 822, 767, 681; HRMS (ESI) calcd. for C19H18F2O2 [M + H]+ 317.1353, found: 317.1359.
3-(2,2-Difluoro-2-(m-tolyl)ethyl)chroman-4-one (3ae), 36.3 mg, 55% yield, light yellow oil; 1H NMR (500 MHz, CDCl3) δ 7.91 (dd, J = 7.9, 1.7 Hz, 1H), 7.49 (ddd, J = 8.5, 7.2, 1.8 Hz, 1H), 7.03 (ddd, J = 8.1, 7.3, 1.0 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.87 (s, 2H), 4.86 (dd, J = 11.3, 5.2 Hz, 1H), 4.34 (t, J = 11.6 Hz, 1H), 3.34 (dddd, J = 11.8, 8.5, 5.2, 2.7 Hz, 1H), 3.04 (dddd, J = 33.1, 15.9, 7.2, 2.7 Hz, 1H), 2.43 (t, J = 4.4 Hz, 6H), 2.27 (s, 3H), 2.16–2.01 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −85.20– −86.00 (m), −88.96 (dd, J = 250.6, 28.9 Hz); 13C NMR (125 MHz, CDCl3) δ 192.5, 161.7, 139.0, 136.0, 136.0 (t, 3JC-F = 3.6 Hz), 131.2, 130.9 (t, 2JC-F = 23.6 Hz), 127.5, 125.4 (t, 1JC-F = 244.3 Hz), 121.5, 120.5, 117.9, 70.8 (d, 3JC-F = 4.7 Hz), 41.0, 33.7 (t, 2JC-F = 26.7 Hz), 22.2 (t, 3JC-F = 6.5 Hz), 20.7; IR (KBr): 3027, 2926, 1693, 1604, 1467, 1375, 1160, 1037, 860, 761; HRMS (ESI) calcd. for C20H20F2O2 [M + H]+ 331.1510, found: 331.1511.
3-(2-(Benzo[d][1,3]dioxol-5-yl)-2,2-difluoroethyl)chroman-4-one (3aj), 27.6 mg, 41% yield, light yellow solid; mp 46.3–46.5 °C; 1H NMR (500 MHz, CDCl3) δ 7.87 (dd, J = 7.9, 1.7 Hz, 1H), 7.47 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 7.06–6.92 (m, 4H), 6.83 (d, J = 8.1 Hz, 1H), 5.99 (s, 2H), 4.72 (dd, J = 11.4, 5.0 Hz, 1H), 4.24 (t, J = 11.7 Hz, 1H), 3.17–2.93 (m, 2H), 2.11–1.98 (m, 1H); 19F NMR (470 MHZ, CDCl3) δ −87.57 (ddd, J = 244.5, 23.5, 8.1 Hz), −95.50 (ddd, J = 244.3, 21.7, 16.7 Hz); 13C NMR (125 MHz, CDCl3) δ 192.1, 161.6, 149.0, 148.0, 136.1, 130.4 (t, 2JC-F = 26.6 Hz), 127.5, 122.6 (t, 1JC-F = 243.1 Hz), 121.5, 120.4, 119.0 (t, 3JC-F = 6.8 Hz), 117.8, 108.2, 105.7 (t, 3JC-F = 6.2 Hz), 101.6, 70.5, 41.3, 34.3 (t, 2JC-F = 28.5 Hz); IR (KBr): 3045, 2920, 1691, 1604, 1498, 1447, 1101, 1038, 815, 758, 664; HRMS (ESI) calcd. for C18H14F2O4 [M + H]+ 333.0938, found: 333.0934.
3-(2,2-Difluoro-2-(4-fluorophenyl)ethyl)chroman-4-one (3ak), 24.5 mg, 40% yield, white solid; mp 93.6–93.9 °C; 1H NMR (500 MHz, CDCl3) δ 7.88 (dd, J = 7.9, 1.7 Hz, 1H), 7.53 (dd, J = 8.8, 5.2 Hz, 2H), 7.48 (ddd, J = 8.6, 7.2, 1.8 Hz, 1H), 7.12 (t, J = 8.6 Hz, 2H), 7.06–6.99 (m, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.75 (dd, J = 11.3, 5.2 Hz, 1H), 4.26 (t, J = 11.6 Hz, 1H), 3.22–2.93 (m, 1H), 2.24–1.89 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −88.92 (ddd, J = 247.0, 24.8, 7.1 Hz), −96.62 (ddd, J = 246.6, 22.5, 15.7 Hz), −110.5; 13C NMR (125 MHz, CDCl3) δ 192.0, 163.6 (d, 1JC-F = 250.0 Hz), 161.6, 136.1, 132.6 (td, 2JC-F = 26.8 Hz, 4JC-F = 3.2 Hz), 127.5, 127.2 (dt, 3JC-F = 6.3 Hz, 3JC-F = 6.2 Hz), 122.9 (t, 1JC-F = 243.3 Hz), 121.6, 120.3, 117.8, 115.8 (d, 2JC-F = 22.0 Hz), 70.5, 41.2, 34.3 (t, 2JC-F = 28.0 Hz); IR (KBr): 3069, 2922, 1696, 1609, 1515, 1472, 1237, 1164, 1099, 832, 754; HRMS (ESI) calcd. for C17H13F3O2 [M + H]+ 307.0946, found: 307.0945.
3-(2-(3-Bromophenyl)-2,2-difluoroethyl)chroman-4-one (3an), 19.1 mg, 26% yield, white solid; mp 60.1–60.4 °C; 1H NMR (500 MHz, CDCl3) δ 7.88 (dd, J = 8.0, 1.6 Hz, 1H), 7.69 (s, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.51–7.45 (m, 2H), 7.33 (t, J = 7.9 Hz, 1H), 7.03 (ddd, J = 8.0, 7.2, 1.0 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.77 (dd, J = 11.3, 5.2 Hz, 1H), 4.27 (t, J = 11.7 Hz, 1H), 3.21–2.94 (m, 2H), 2.17–1.97 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −90.78 (ddd, J = 246.6, 26.2, 7.6 Hz), −97.89 (ddd, J = 246.6, 23.7, 14.5 Hz); 13C NMR (125 MHz, CDCl3) δ 191.9, 161.7, 138.7 (t, 2JC-F = 26.9 Hz), 136.2, 133.3, 130.3, 128.2 (t, 3JC-F = 6.4 Hz), 127.6, 123.6 (t, 3JC-F = 6.0 Hz), 122.8, 121.8 (t, 1JC-F = 243.9 Hz), 121.6, 120.3, 117.8, 70.5, 41.1, 34.3 (t, 2JC-F = 27.5 Hz); IR (KBr): 3035, 2923, 1693, 1603, 1470, 1120, 1064, 1001, 794, 753, 689, 591; HRMS (ESI) calcd. for C17H13BrF2O2 [M + H]+ 367.0145, found: 367.0141.
3-(2,2-Difluoro-2-(4-iodophenyl)ethyl)chroman-4-one (3ao), 49.7 mg, 60% yield, light yellow solid; mp 116.0–116.5 °C; 1H NMR (500 MHz, CDCl3) δ 7.87 (dd, J = 8.2, 1.7 Hz, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.47 (ddd, J = 8.4, 7.2, 1.8 Hz, 1H), 7.27 (d, J = 8.3 Hz, 2H), 7.01 (ddd, J = 8.1, 7.2, 1.0 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.74 (dd, J = 11.4, 5.1 Hz, 1H), 4.25 (t, J = 11.6 Hz, 1H), 3.16–2.96 (m, 2H), 2.10–1.99 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −90.34 (ddd, J = 246.9, 24.9, 7.7 Hz), −97.88 (ddd, J = 246.8, 22.8, 15.4 Hz); 13C NMR (125 MHz, CDCl3) δ 191.9, 161.6, 137.9, 136.2, 136.2 (t, 2JC-F = 26.6 Hz), 127.6, 126.7 (t, 3JC-F = 5.8 Hz), 122.4 (t, 1JC-F = 243.6 Hz), 121.6, 120.3, 117.8, 96.6, 70.4, 41.1, 34.1 (t, 2JC-F = 27.8 Hz); IR (KBr): 3009, 2905, 1689, 1595, 1466, 1112, 1021, 826, 763, 555; HRMS (ESI) calcd. for C17H13F2IO2 [M + H]+ 415.0007, found: 415.0011.
3-(2,2-Difluoro-2-((4-methoxyphenyl)thio)ethyl)chroman-4-one (3aq), 21.0 mg, 30% yield, white solid; mp 67.5–68.0 °C; 1H NMR (500MHz, CDCl3) δ 7.89 (dd, J = 7.9, 1.7 Hz, 1H), 7.53 (d, J = 8.8 Hz, 2H), 7.49 (ddd, J = 8.8, 7.2, 1.8 Hz, 1H), 7.03 (ddd, J = 8.0, 7.3, 1.0 Hz, 1H), 6.98 (d, J = 9.1 Hz, 1H), 6.91 (d, J = 8.9 Hz, 2H), 4.75 (dd, J = 11.4, 5.3 Hz, 1H), 4.22 (t, J = 11.8 Hz, 1H), 3.83 (s, 3H), 3.33–3.19 (m, 1H), 3.11–3.00 (m, 1H), 2.15–1.95 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −69.65 (ddd, J = 207.3, 19.6, 8.6 Hz), −74.59 (dt, J = 207.2, 17.4 Hz); 13C NMR (125 MHz, CDCl3) δ 191.6, 161.6, 161.3, 138.2, 136.1, 129.4 (t, 1JC-F = 278.2 Hz), 127.6, 121.6, 120.3, 117.8, 116.8, 114.8, 70.3, 55.4, 41.7, 33.8 (t, 2JC-F = 24.6 Hz); IR (KBr): 3052, 2929, 1688, 1596, 1469, 1394, 1153, 1026, 960, 823, 761; HRMS (ESI) calcd. for C18H16F2O3S [M + H]+ 351.0866, found: 351.0865.
2-((2,2-Difluoro-6-methoxythiochroman-4-yl)methoxy)benzaldehyde (3aq’), 20.3 mg, 29% yield, white solid; mp 64.0–64.5 °C; 1H NMR (500MHz, CDCl3) δ 10.48 (s, 1H), 7.84 (dd, J = 7.7, 1.8 Hz, 1H), 7.54 (ddd, J = 9.1, 7.4, 1.8 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 2.7 Hz, 1H), 6.83 (dd, J = 8.6, 2.7 Hz, 1H), 4.46–4.31 (m, 2H), 3.78 (s, 3H), 3.61–3.56 (m, 1H), 2.81–2.72 (m, 1H), 2.66–2.58 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −60.89 (ddd, J = 219.7, 22.1, 13.6 Hz), −64.51 (dt, J = 219.8, 12.3 Hz); 13C NMR (125 MHz, CDCl3) δ 189.2, 160.6, 158.4, 136.0, 134.5, 130.5 (t, 1JC-F = 268.7 Hz) 128.8, 128.3 (t, 3JC-F = 2.9 Hz), 125.0, 121.3, 120.8, 115.1, 113.7, 112.5, 68.2 (d, 3JC-F = 3.4 Hz), 55.5, 39.0 (d, 3J = 5.6 Hz), 37.6 (t, 2JC-F = 23.8 Hz); IR (KBr): 3067, 2926, 1739, 1678, 1599, 1568, 1496, 1074, 1022, 990, 890, 806, 760; HRMS (ESI) calcd. for C18H16F2O3S [M + H]+ 351.0866, found: 351.0863.
3-(2,2-Difluorobutyl)chroman-4-one (3ar), 6.3 mg, 13% yield, light yellow oil; 1H NMR (500 MHz, CDCl3) δ 7.90 (dd, J = 7.9, 1.8 Hz, 1H), 7.53–7.44 (m, 1H), 7.02 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.76 (dd, J = 11.4, 5.2 Hz, 1H), 4.24 (t, J = 11.7 Hz, 1H), 3.17 (dddd, J = 12.1, 8.9, 5.3, 3.0 Hz, 1H), 2.74 (dddd, J = 29.4, 15.4, 10.9, 3.0 Hz, 1H), 2.00–1.87 (m, 2H), 1.80 (dddd, J = 24.8, 15.8, 9.3, 6.9 Hz, 1H), 1.06 (t, J = 7.5 Hz, 3H); 19F NMR (470 MHz, CDCl3) δ −96.70–−98.13 (m), −100.51–−101.83 (m); 13C NMR (125 MHz, CDCl3) δ 192.6, 161.7, 136.0, 127.5, 125.0 (t, 1JC-F = 242.0 Hz), 121.5, 120.4, 117.8, 70.7, 40.9, 31.3 (t, 2JC-F = 25.4 Hz), 30.5 (t, 2JC-F = 26.0 Hz), 6.6 (t, 3JC-F = 5.7 Hz); IR (KBr): 3041, 2928, 1694, 1609, 1468, 1370, 1137, 1040, 764, 673; HRMS (ESI) calcd. for C13H14F2O2 [M + H]+ 241.1040, found: 241.1037.
3-(2,2-Difluoro-2-(4-methoxyphenyl)ethyl)-7-methoxychroman-4-one (3bb), 36.2 mg, 52% yield, white solid; mp 105.9–106.1 °C; 1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 8.8 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 6.57 (dd, J = 8.6, 2.6 Hz, 1H), 6.39 (d, J = 2.3 Hz, 1H), 4.70 (dd, J = 11.2, 5.2 Hz, 1H), 4.22 (t, J = 11.5 Hz, 1H), 3.82 (s, 6H), 3.32–2.85 (m, 2H), 2.31–1.82 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.41 (ddd, J = 245.4, 23.5, 8.1 Hz), −95.84 (dt, J = 248.5, 20.6 Hz); 13C NMR (125 MHz, CDCl3) δ 190.8, 166.0, 163.6, 160.8, 129.2, 128.8 (t, 2JC-F = 26.8 Hz), 126.4 (t, 3JC-F = 6.1 Hz), 123.0 (t, 1JC-F = 242.2 Hz), 114.2, 113.9, 110.1, 100.6, 70.9, 55.6, 55.4, 40.9, 34.3 (t, 2JC-F = 28.5 Hz); IR (KBr): 3021, 2957, 1690, 1614, 1511, 1460, 1374, 1614, 1167, 1026, 879, 830; HRMS (ESI) calcd. For C19H18F2O4 [M + H]+ 349.1251, found: 349.1248.
3-(2,2-Difluoro-2-(4-methoxyphenyl)ethyl)-6-methylchroman-4-one (3cb), 23.3 mg, 35% yield, white solid; mp 69.6–70.1 °C; 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 1.9 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.28 (dd, J = 8.9, 2.3 Hz, 1H), 6.94 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.5 Hz, 1H), 4.69 (dd, J = 11.2, 5.1 Hz, 1H), 4.21 (t, J = 11.5 Hz, 1H), 3.83 (s, 3H), 3.21–2.94 (m, 2H), 2.30 (s, 3H), 2.12–2.00 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.69 (ddd, J = 245.5, 23.3, 8.2 Hz), −95.74 (ddd, J = 245.5, 21.5, 16.7 Hz); 13C NMR (125 MHz, CDCl3) δ 192.4, 160.8, 159.7, 137.1, 130.9, 128.8 (t, 2JC-F = 26.8 Hz), 127.0, 126.4 (t, 3JC-F = 6.1 Hz), 122.9 (t, 1JC-F = 242.2 Hz), 120.0, 117.6, 113.9, 70.5, 55.4, 41.4, 34.3 (t, 2JC-F = 28.8 Hz), 20.4; IR (KBr): 3027, 2916, 1697, 1617, 1501, 1424, 1302, 1169, 1028, 823, 735; HRMS (ESI) calcd. for C19H18F2O3 [M + H]+ 333.1302, found: 333.1306.
3-(2,2-Difluoro-2-(4-methoxyphenyl)ethyl)-7-methylchroman-4-one (3db), 33.2 mg, 50% yield, white solid; mp 64.4–64.7 °C; 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.82 (ddd, J = 8.0, 1.5, 0.5 Hz, 1H), 6.76 (s, 1H), 4.70 (dd, J = 11.4, 5.2 Hz, 1H), 4.21 (t, J = 11.6 Hz, 1H), 3.82 (s, 3H), 3.20–2.88 (m, 2H), 2.35 (s, 3H), 2.05 (dddd, J = 22.4, 15.9, 9.7, 8.7 Hz, 1H); 19F NMR (470 MHz, CDCl3) δ −87.58 (ddd, J = 245.5, 23.2, 8.1 Hz), −95.75 (ddd, J = 245.4, 21.5, 16.8 Hz); 13C NMR (125 MHz, CDCl3) δ 191.9, 161.7, 160.8, 147.6, 128.8 (t, 2JC-F = 26.9 Hz), 127.4, 126.4 (t, 3JC-F = 6.1 Hz), 122.9 (t, 1JC-F = 242.0 Hz), 122.9, 118.1, 117.8, 113.9, 70.5, 55.4, 41.2, 34.2 (t, 2JC-F = 28.6 Hz), 21.9; IR (KBr): 3019, 2934, 1684, 1612, 1513, 1319, 1167, 974, 827; HRMS (ESI) calcd. for C19H18F2O3 [M + H]+ 333.1302, found: 333.1300.
6,8-Di-tert-butyl-3-(2,2-difluoro-2-(4-methoxyphenyl)ethyl)chroman-4-one (3eb), 38.8 mg, 45% yield, light yellow oil; 1H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 2.5 Hz, 1H), 7.54 (d, J = 2.6 Hz, 1H), 7.48 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 4.79 (s, 1H), 4.22 (t, J = 11.5 Hz, 1H), 3.83 (s, 3H), 3.18–2.97 (m, 2H), 2.18–2.00 (m, 1H), 1.40 (s, 9H), 1.30 (s, 9H); 19F NMR (470 MHz, CDCl3) δ −87.06 (ddd, J = 245.5, 23.6, 7.9 Hz), −95.98 (ddd, J = 245.5, 21.8, 16.8 Hz); 13C NMR (125 MHz, CDCl3) δ 193.2, 160.8, 158.8, 143.4, 138.3, 130.8, 128.9 (t, 2JC-F = 26.8 Hz), 126.5 (t, 3JC-F = 6.1 Hz), 123.0 (t, 1JC-F = 242.4 Hz), 121.5, 120.4, 113.9, 70.0, 55.4, 41.3, 35.1, 34.5, 34.4 (t, 2JC-F = 28.4 Hz), 31.3, 29.7; IR (KBr): 3006, 2920, 1682, 1613, 1471, 1364, 1171, 1023, 846, 758, 678; HRMS (ESI) calcd. for C26H32F2O3 [M + H]+ 431.2398, found: 431.2395.
3-(2,2-Difluoro-2-(4-methoxyphenyl)ethyl)-6-fluorochroman-4-one (3fb), 34.3 mg, 51% yield, white solid; mp 112.4–112.8 °C; 1H NMR (500 MHz, CDCl3) δ 7.52 (dd, J = 8.3, 3.2 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.20 (ddd, J = 9.1, 7.7, 3.2 Hz, 1H), 6.95 (dd, J = 8.6, 5.0 Hz, 3H), 4.73 (dd, J = 11.7, 5.2 Hz, 1H), 4.23 (t, J = 11.8 Hz, 1H), 3.83 (s, 3H), 3.15–3.00 (m, 2H), 2.13–2.00 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.90 (ddd, J = 245.6, 23.8, 8.2 Hz), −95.81 (ddd, J = 245.5, 21.9, 16.3 Hz), -121.27 (td, J = 8.1, 4.3 Hz); 13C NMR (125 MHz, CDCl3) δ 191.5, 160.9, 158.2, 157.9 (d, 4JC-F = 1.7 Hz), 156.3, 128.6 (t, 2JC-F = 26.8 Hz), 126.4 (dd, 3JC-F = 6.4Hz, J = 5.6Hz), 123.6 (d, 2JC-F = 24.6 Hz), 122.7 (t, 1JC-F = 242.1 Hz), 120.7 (d, 3JC-F = 6.6 Hz), 119.5 (d, 3JC-F = 7.3 Hz), 112.4 (d, 2JC-F = 23.4 Hz), 70.7, 55.6, 41.2, 34.2 (dd, 2JC-F = 29.2, 28.0 Hz); IR (KBr): 3061, 2939, 1686, 1619, 1487, 1441, 1380, 1122, 1020, 897, 822, 744; HRMS (ESI) calcd. for C18H15F3O3 [M + H]+ 337.1052, found: 337.1049.
6-Chloro-3-[2,2-difluoro-2-(4-methoxy-phenyl)-ethyl]-chroman-4-one (3gb), 39.5 mg, 56% yield, white solid; mp 116.1–116.5 °C; 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 2.7 Hz, 1H), 7.45 (d, J = 8.8 Hz, 2H), 7.41 (dd, J = 8.8, 2.7 Hz, 1H), 6.93 (dd, J = 8.8, 5.7 Hz, 3H), 4.74 (dd, J = 11.6, 5.2 Hz, 1H), 4.23 (t, J = 11.7 Hz, 1H), 3.83 (s, 3H), 3.15–3.00 (m, 2H), 2.12–1.98 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.93 (ddd, J = 245.8, 24.0, 8.1 Hz), −95.83 (ddd, J = 245.5, 22.0, 16.1 Hz); 13C NMR (125 MHz, CDCl3) δ 191.1, 160.9, 160.1, 135.9, 128.7 (t, 2JC-F= 26.9 Hz), 127.0, 126.8, 126.4 (t, 3JC-F = 6.1 Hz), 122.7 (t, 1JC-F = 242.3 Hz), 121.1, 119.6, 114.0, 70.6, 55.4, 41.2, 34.2 (t, 2JC-F = 28.9 Hz); IR (KBr): 3087, 2921, 1698, 1610, 1571, 1515, 1472, 1381, 1104, 1022, 889, 826, 776, 426; HRMS (ESI) calcd. for C18H15ClF2O3 [M + H]+ 353.0756, found: 353.0753.
6-Bromo-3-(2,2-difluoro-2-(4-methoxyphenyl)ethyl)chroman-4-one (3hb), 43.7 mg, 55% yield, white solid; mp 125.4–125.7 °C; 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 2.5 Hz, 1H), 7.54 (dd, J = 8.8, 2.6 Hz, 1H), 7.45 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 1H), 4.75 (dd, J = 11.5, 5.1 Hz, 1H), 4.23 (t, J = 11.7 Hz, 1H), 3.83 (s, 3H), 3.18–2.96 (m, 2H), 2.19–1.91 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.93 (ddd, J = 245.7, 24.0, 8.0 Hz), −95.83 (ddd, J = 245.5, 22.0, 16.0 Hz); 13C NMR (125 MHz, CDCl3) δ 191.0, 160.9, 160.5, 138.7, 129.9, 128.6 (t, 2JC-F= 26.9 Hz), 126.4 (t, 3JC-F = 5.9 Hz), 122.7 (t, 1JC-F = 242.2 Hz), 121.6, 119.9, 114.1, 114.0, 70.6, 55.4, 41.1, 34.2 (t, 2JC-F = 28.7 Hz); IR (KBr): 3083, 2908, 1697, 1608, 1515, 1470, 1103, 1023, 889, 824, 777, 675; HRMS (ESI) calcd. for C18H15BrF2O3 [M + H]+ 397.0251, found: 397.0253.
7-Chloro-3-(2,2-difluoro-2-(4-methoxyphenyl)ethyl)chroman-4-one (3ib), 45.2 mg, 64% yield, white solid; mp 116.3–116.6 °C; 1H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 8.9 Hz, 1H), 7.45 (d, J = 8.7 Hz, 2H), 7.00–6.97 (m, 2H), 6.94 (d, J = 8.7 Hz, 2H), 4.75 (dd, J = 11.7, 5.2 Hz, 1H), 4.24 (t, J = 11.8 Hz, 1H), 3.82 (s, 3H), 3.17–2.97 (m, 2H), 2.15–1.95 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.90 (ddd, J = 245.6, 23.9, 8.2 Hz), −95.75 (ddd, J = 245.6, 21.9, 16.2 Hz); 13C NMR (125MHz, CDCl3) δ 191.2, 162.0, 160.9, 141.9, 128.8, 128.6 (t, 2JC-F = 26.8 Hz), 126.4 (t, 3JC-F = 6.1 Hz), 122.8 (t, 1JC-F = 242.0 Hz), 122.3, 118.9, 118.0, 114.0, 70.8, 55.4, 41.2, 34.2 (t, 2JC-F = 28.6 Hz); IR (KBr): 3012, 2949, 1674, 1605, 1516, 1468, 1379, 1069, 1025, 934, 834, 806, 705, 579, 448; HRMS (ESI) calcd. for C18H15ClF2O3 [M + H]+ 353.0756, found: 353.0755.
8-Chloro-3-(2,2-difluoro-2-(4-methoxyphenyl)ethyl)chroman-4-one (3jb), 24.7 mg, 35% yield, light yellow solid; mp 76.1–76.8 °C; 1H NMR (500 MHz, CDCl3) δ 7.80 (dd, J = 8.0, 1.6 Hz, 1H), 7.56 (dd, J = 8.0, 1.6 Hz, 1H), 7.46 (d, J = 9.2 Hz, 2H), 7.00–6.91 (m, 3H), 4.89 (dd, J = 11.2, 5.2 Hz, 1H), 4.31 (t, J = 11.6 Hz, 1H), 3.83 (s, 3H), 3.23–2.95 (m, 2H), 2.15–2.01 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.87 (ddd, J = 245.9, 23.0, 8.2 Hz), −95.55 (ddd, J = 246.0, 21.4, 16.8 Hz); 13C NMR (125 MHz, CDCl3) δ 191.3, 160.9, 157.1, 136.1, 128.5 (t, 2JC-F = 26.8 Hz), 126.4 (t, 3JC-F = 6.1 Hz), 126.1, 122.7 (t, 1JC-F = 242.4 Hz), 122.6, 121.6, 121.6, 114.0, 71.1, 55.4, 41.2, 34.1 (t, 2JC-F = 28.9 Hz); IR (KBr): 3074, 2924, 1682, 1608, 1450, 1515, 1374, 1115, 1023, 835, 767, 730, 595, 432; HRMS (ESI) calcd. for C18H15ClF2O3 [M + H]+ 353.0756, found: 353.0759.
3-(2,2-Cifluoro-2-(4-methoxyphenyl)ethyl)-6-iodochroman-4-one (3kb), 35.5 mg, 40% yield, white solid; mp 130.1–131.1 °C; 1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 2.2 Hz, 1H), 7.70 (dd, J = 8.7, 2.3 Hz, 1H), 7.44 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 6.74 (d, J = 8.7 Hz, 1H), 4.74 (dd, J = 11.5, 5.1 Hz, 1H), 4.22 (t, J = 11.7 Hz, 1H), 3.82 (s, 3H), 3.14–2.99 (m, 2H), 2.10–1.99 (m, 2H); 19F NMR (470 MHz, CDCl3) δ −87.86 (ddd, J = 245.8, 24.0, 7.8 Hz), −95.71 (ddd, J = 245.5, 21.8, 16.2 Hz); 13C NMR (125 MHz, CDCl3) δ 190.8, 161.2, 160.9, 144.3, 136.1, 128.6 (t, 2JC-F = 26.7 Hz), 126.4 (t, 3JC-F = 6.1 Hz), 122.7 (t, 1JC-F = 242.3 Hz), 122.2, 120.2, 114.0, 83.8, 70.5, 55.4, 41.0, 34.2 (t, 2JC-F = 28.7 Hz); IR (KBr): 3078, 2902, 1692, 1592, 1514, 1101, 1027, 893, 823, 781, 571; HRMS (ESI) calcd. for C18H15F2IO3 [M + H]+ 445.0122, found: 445.0124.
6,8-Dibromo-3-(2,2-difluoro-2-(4-methoxyphenyl)ethyl)chroman-4-one (3lb), 17.1 mg, 18% yield, white solid; mp 125.2–125.4 °C; 1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 2.4 Hz, 1H), 7.83 (d, J = 2.4 Hz, 1H), 7.44 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 4.90 (dd, J = 11.5, 5.4 Hz, 1H), 4.30 (t, J = 12.0 Hz, 1H), 3.83 (s, 3H), 3.21–2.97 (m, 2H), 2.20–1.96 (m, 1H); 19F NMR (470 MHz, CDCl3) δ −87.96 (ddd, J = 25.8, 23.4, 7.7 Hz), −95.58 (ddd, J = 245.8, 21.4, 16.2 Hz); 13C NMR (125 MHz, CDCl3) δ 190.2, 160.9, 157.1, 141.1, 129.4, 128.4 (t, 2JC-F = 26.6 Hz), 126.4 (t, 3J C-F = 6.0 Hz), 122.6 (t, 1JC-F = 241.7 Hz), 122.2, 114.0, 112.6, 71.2, 55.4, 40.8, 34.1 (t, 2JC-F = 28.9 Hz); IR (KBr): 3063, 2939, 1685, 1614, 1515, 1438, 1114, 1022, 894, 837, 806, 767, 576; HRMS (ESI) calca. For C18H14Br2F2O3 [M + H]+ 474.9356, found: 474.9353.
3-(2,2-Difluoro-2-(4-methoxyphenyl)ethyl)-3-methylchroman-4-one (3mb), 27.3 mg, 41% yield, light yellow oil; 1H NMR (500 MHz, CDCl3) δ 7.89 (dd, J = 7.9, 1.8 Hz, 1H), 7.48 (ddd, J = 8.4, 7.2, 1.8 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.03 (ddd, J = 8.0, 7.2, 1.0 Hz, 1H), 6.98 (dd, J = 8.4, 0.7 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H), 4.58 (d, J = 11.6 Hz, 1H), 4.35 (d, J = 11.7 Hz, 1H), 3.82 (s, 3H), 2.74 (ddd, J = 29.9, 15.7, 7.9 Hz, 1H), 2.42 (ddd, J = 26.9, 15.7, 11.5 Hz, 1H), 1.32 (s, 3H); 19F NMR (470 MHz, CDCl3) δ −89.01 (ddd, J = 243.5, 29.9, 11.5 Hz), −90.24 (ddd, J = 243.3, 26.7, 7.9 Hz); 13C NMR (125 MHz, CDCl3) δ 195.2, 161.0, 160.6, 135.7, 130.0 (t, 2JC-F = 26.7 Hz), 128.1, 126.3 (t, 3JC-F = 6.3 Hz), 122.9 (t, 1JC-F =244.2 Hz), 121.6, 119.3, 117.7, 113.7, 74.5, 55.3, 44.1, 41.7 (t, 2JC-F = 27.6 Hz), 19.8; IR (KBr): 3072, 2932, 1690, 1611, 1515, 1467, 1363, 1111, 1031, 829, 764; HRMS (ESI) calcd. for C19H18F2O3 [M + H]+ 333.1302, found: 333.1306.
2-(2,2-Difluoro-2-(p-tolyl)ethyl)-2,3-dihydro-1H-inden-1-one (3na), 21.1mg, 37% yield, white solid; mp 122.8–123.3 °C; 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 7.7 Hz, 1H), 7.43 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 7.1 Hz, 1H), 7.24 (d, J = 7.9 Hz, 2H), 3.44 (dd, J = 17.5, 8.1 Hz, 1H), 3.08–2.92 (m, 2H), 2.90–2.81 (m, 1H), 2.39 (s, 3H), 2.14 (dddd, J = 20.7, 14.9, 11.5, 8.0 Hz, 1H); 19F NMR (470 MHz, CDCl3) δ −90.63 (ddd, J = 244.7, 21.8, 7.9 Hz), −96.99 (ddd, J = 244.6, 20.3, 16.9 Hz); 13C NMR (125 MHz, CDCl3) δ 206.6, 153.7, 140.0, 136.0, 135.0, 134.1 (t, 2JC-F = 26.4 Hz), 129.2, 127.5, 126.5, 124.8 (t, 3JC-F = 6.2 Hz), 124.0, 123.2 (t,1JC-F = 242.7 Hz), 42.9, 40.2 (t, 2JC-F = 27.8 Hz), 33.9, 21.3; IR (KBr): 3054, 2924, 1711, 1597, 1460, 1080, 1021, 849, 811, 760; HRMS (ESI) calcd. for C18H16F2O [M + H]+ 287.1247, found: 287.1243.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28083578/s1, [34,42,44,45,46], Table S1: Screening the reaction time; Table S2: Screening the reaction temp; Figure S1: Crystal structure of 3aq′; Table S3: Sample and crystal data for 3aq′; Table S4: Bond lengths (Å) for 3aq′; Table S5: Bond angles (°) for 3aq′; Figure S2: Copies of 1H NMR, 19F NMR and 13C NMR spectra of all compounds.

Author Contributions

Conceptualization, H.J.; methodology, H.J. and J.H.; validation, H.J. and Q.S.; formal analysis, Q.S. and H.D.; investigation Q.S., H.L. and X.C.; writing—original draft preparation, H.J. and Q.S.; writing—review and editing, H.J. and J.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are contained in the article tables and Supplementary Materials.

Acknowledgments

We thank the Instrumental Analysis and Research Center of Shanghai University for assistance.

Conflicts of Interest

The authors declare that they have no known competing financial interest or personal relationships that could have appeared to influence the work reported in this paper.

Sample Availability

Samples of the compounds 3 are available from the authors.

References

  1. Emami, S.; Ghanbarimasir, Z. Recent advances of chroman-4-one derivatives: Synthetic approaches and bioactivities. Eur. J. Med. Chem. 2015, 93, 539–563. [Google Scholar] [CrossRef]
  2. Fridén Saxin, M.; Seifert, T.; Landergren, M.R.; Suuronen, T.; Lahtela Kakkonen, M.; Jarho, E.M.; Luthman, K. Synthesis and evaluation of substituted chroman-4-one and chromone derivatives as sirtuin 2-selective inhibitors. J. Med. Chem. 2012, 55, 7104–7113. [Google Scholar] [CrossRef] [PubMed]
  3. Godlewski, G.; Offertaler, L.; Wagner, J.A.; Kunos, G. Receptors for acylethanolamides-GPR55 and GPR119. Prostag. Oth. Lipid Mediat. 2009, 89, 105–111. [Google Scholar] [CrossRef]
  4. McKee, T.C.; Bokesch, H.R.; McCormick, J.L.; Rashid, M.A.; Spielvogel, D.; Gustafson, K.R.; Alavanja, M.M.; Cardellina, J.H.; Boyd, M.R. Isolation and characterization of new anti-HIV and cytotoxic leads from plants, marine, and microbial organisms. J. Nat. Prod. 1997, 60, 431–438. [Google Scholar] [CrossRef]
  5. Hu, Q.F.; Niu, D.Y.; Zhou, B.; Ye, Y.Q.; Du, G.; Meng, C.Y.; Gao, X.M. Isoflavanones from the stem of cassia siamea and their anti-tobacco mosaic virus activities. Bull. Korean Chem. Soc. 2013, 34, 3013–3016. [Google Scholar] [CrossRef]
  6. Li, C.; Cao, Y.X.; Wang, R.; Wang, Y.N.; Lan, Q.; Wang, X.S. Cobalt-catalyzed difluoroalkylation of tertiary aryl ketones for facile synthesis of quaternary alkyl difluorides. Nat. Commun. 2018, 9, 4951. [Google Scholar] [CrossRef] [PubMed]
  7. Hirano, K.; Biju, A.T.; Piel, I.; Glorius, F. N-Heterocyclic carbene-catalyzed hydroacylation of unactivated double bonds. J. Am. Chem. Soc. 2009, 131, 14190–14191. [Google Scholar] [CrossRef]
  8. Hu, H.; Chen, X.; Sun, K.; Wang, J.; Liu, Y.; Liu, H.; Fan, L.; Yu, B.; Sun, Y.; Qu, L.; et al. Silver-Catalyzed radical cascade cyclization toward 1,5-/1,3-dicarbonyl heterocycles: An atom-/step-economical strategy leading to chromenopyridines and isoxazole-/pyrazole-containing chroman-4-ones. Org. Lett. 2018, 20, 6157–6160. [Google Scholar] [CrossRef]
  9. Li, K.; Chen, J.; Yang, C.; Zhang, K.; Pan, C.; Fan, B. Blue light promoted difluoroalkylation of aryl ketones: Synthesis of quaternary alkyl difluorides and tetrasubstituted monofluoroalkenes. Org. Lett. 2020, 22, 4261–4265. [Google Scholar] [CrossRef]
  10. Xie, L.-Y.; Peng, S.; Yang, L.-H.; Liu, X.-W. Metal-Free Synthesis of Carbamoylated Chroman-4-Ones via Cascade Radical Annulation of 2-(Allyloxy)arylaldehydes with Oxamic Acids. Molecules 2022, 27, 7049. [Google Scholar] [CrossRef]
  11. Sheng, J.; Liu, J.; Chen, L.; Zhang, L.; Zheng, L.; Wei, X. Silver-catalyzed cascade radical cyclization of 2-(allyloxy)arylaldehydes with cyclopropanols: Access to chroman-4-one derivatives. Org. Chem. Front. 2019, 6, 1471–1475. [Google Scholar] [CrossRef]
  12. Mei, Y.; Zhao, L.; Liu, Q.; Ruan, S.; Wang, L.; Li, P. Synthesis of sulfone-functionalized chroman-4-ones and chromans through visible-light-induced cascade radical cyclization under transition-metal-free conditions. Green Chem. 2020, 22, 2270–2278. [Google Scholar] [CrossRef]
  13. Pan, X.; Xia, H.; Wu, J. Recent advances in photoinduced trifluoromethylation and difluoroalkylation. Org. Chem. Front. 2016, 3, 1163–1185. [Google Scholar] [CrossRef]
  14. Hollingworth, C.; Gouverneur, V. Transition metal catalysis and nucleophilic fluorination. Chem. Commun. 2012, 48, 2929–2942. [Google Scholar] [CrossRef]
  15. Ni, C.; Hu, M.; Hu, J. Good partnership between sulfur and fluorine: Sulfur-Based fluorination and fluoroalkylation reagents for organic synthesis. Chem. Rev. 2015, 115, 765–825. [Google Scholar] [CrossRef]
  16. Hu, J.; Zhang, W.; Wang, F. Selective difluoromethylation and monofluoromethylation reactions. Chem. Commun. 2009, 7465–7478. [Google Scholar] [CrossRef]
  17. Tozer, M.J.; Herpin, T.F. Methods for the synthesis of gem-difluoromethylene compounds. Tetrahedron 1996, 52, 8619–8683. [Google Scholar] [CrossRef]
  18. Wang, J.; Sánchez Roselló, M.; Aceña, J.L.; Del Pozo, C.; Sorochinsky, A.E.; Fustero, S.; Soloshonok, V.A.; Liu, H. Fluorine in pharmaceutical industry: Fluorine-Containing drugs introduced to the market in the last decade (2001–2011). Chem. Rev. 2014, 114, 2432–2506. [Google Scholar] [CrossRef]
  19. Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: Looking beyond intuition. Science 2007, 317, 1881–1886. [Google Scholar] [CrossRef]
  20. Gillis, E.P.; Eastman, K.J.; Hill, M.D.; Donnelly, D.J.; Meanwell, N.A. Applications of fluorine in medicinal chemistry. J. Med. Chem. 2015, 58, 8315–8359. [Google Scholar] [CrossRef]
  21. Anderson, M.O.; Zhang, J.; Liu, Y.; Yao, C.J.; Phuan, P.W.; Verkman, A.S. Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B. J. Med. Chem. 2012, 55, 5942–5950. [Google Scholar] [CrossRef] [PubMed]
  22. Middleton, W.J.; Bingham, E.M. α,α-DifIuoroarylacetic acids: Preparation from (diethylamino)sulfur trifluoride and α-oxoarylacetates. J. Org. Chem. 1980, 45, 2883–2887. [Google Scholar] [CrossRef]
  23. Umemoto, T.; Singh, R.P.; Xu, Y.; Saito, N. Discovery of 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride as a deoxofluorinating agent with high thermal stability as well as unusual resistance to aqueous hydrolysis, and its diverse fluorination capabilities including deoxofluoro-arylsulfinylation with high stereoselectivity. J. Am. Chem. Soc. 2010, 132, 18199–18205. [Google Scholar]
  24. Lal, G.S.; Pez, G.P.; Pesaresi, R.J.; Prozonic, F.M.; Cheng, H. Bis(2-methoxyethyl)aminosulfur trifluoride: A new broad-spectrum deoxofluorinating agent with enhanced thermal stability. J. Org. Chem. 1999, 64, 7048–7054. [Google Scholar] [CrossRef]
  25. Xia, J.B.; Zhu, C.; Chen, C. Visible light-promoted metal-free C-H activation: Diarylketone-Catalyzed selective benzylic mono- and difluorination. J. Am. Chem. Soc. 2013, 135, 17494–17500. [Google Scholar] [CrossRef] [PubMed]
  26. Xu, C.; Guo, W.H.; He, X.; Guo, Y.L.; Zhang, X.Y.; Zhang, X.G. Difluoromethylation of (hetero)aryl chlorides with chlorodifluoromethane catalyzed by nickel. Nat. Commun. 2018, 9, 1170. [Google Scholar] [CrossRef] [PubMed]
  27. Xiao, Y.L.; Min, Q.Q.; Xu, C.; Wang, R.W.; Zhang, X.G. Nickel-Catalyzed difluoroalkylation of (hetero)arylborons with unactivated 1-bromo-1,1-difluoroalkanes. Angew. Chem. Int. Ed. 2016, 55, 5837–5841. [Google Scholar] [CrossRef] [PubMed]
  28. Min, Q.Q.; Yin, Z.S.; Feng, Z.; Guo, W.H.; Zhang, X.G. Highly selective gem-difluoroallylation of organoborons with bromodifluoromethylated alkenes catalyzed by palladium. J. Am. Chem. Soc. 2014, 136, 1230–1233. [Google Scholar] [CrossRef]
  29. Chen, F.; Hashmi, A.S.K. Silver-Catalyzed decarboxylative alkynylation of α,α-difluoroarylacetic acids with ethynylbenziodoxolone reagents. Org. Lett. 2016, 18, 2880–2882. [Google Scholar] [CrossRef]
  30. Yuan, J.-W.; Zhang, M.-Y.; Liu, Y.; Hu, W.-Y.; Yang, L.-R.; Xiao, Y.-M.; Diao, X.-Q.; Zhang, S.-R.; Mao, J. Transition-metal-free radical difluorobenzylation/cyclization of unactivated alkenes: Access to ArCF2-substituted ring-fused quinazolinones. Org. Biomol. Chem. 2022, 20, 9722–9733. [Google Scholar] [CrossRef]
  31. Zhao, H.; Ma, G.; Xie, X.; Wang, Y.; Hao, J.; Wan, W. Pd(Ⅱ)-Catalyzed decarboxylative meta-C-H difluoromethylation. Chem. Commun. 2019, 55, 3927–3930. [Google Scholar] [CrossRef] [PubMed]
  32. Hong, G.; Yuan, J.; Fu, J.; Pan, G.; Wang, Z.; Yang, L.; Xiao, Y.; Mao, P.; Zhang, X. Transition-metal-free decarboxylative C3-difluoroarylmethylation of quinoxalin-2(1H)-ones with α,α-difluoroarylacetic acids. Org. Chem. Front. 2019, 6, 1173–1182. [Google Scholar] [CrossRef]
  33. Wille, U. Radical cascades initiated by intermolecular radical addition to alkynes and related triple bond systems. Chem. Rev. 2013, 113, 813–853. [Google Scholar] [CrossRef]
  34. Zhou, Y.; Xiong, Z.; Qiu, J.; Kong, L.; Zhu, G. Visible light photocatalytic acyldifluoroalkylation of unactivated alkenes for the direct synthesis of gem-difluorinated ketones. Org. Chem. Front. 2019, 6, 1022–1026. [Google Scholar] [CrossRef]
  35. Zhou, N.; Wu, M.; Zhang, M.; Zhou, X. Visible-light-induced difluoroacetylation of O-(allyloxy) aryl-aldehydes: Access to difluoroacetylated chroman-4-ones. Asian J. Org. Chem. 2019, 8, 828–831. [Google Scholar] [CrossRef]
  36. Huang, H.L.; Du, J.Y.; Li, Q.L.; Gao, F.; Ma, C.L. Visible-light-promoted cascade radical cyclization: Synthesis of chroman-4-ones and dihydroquinolin-4-ones. J. Org. Chem. 2020, 85, 3963–3972. [Google Scholar] [CrossRef]
  37. Wang, P.; Du, P.; Sun, Q.; Zhang, J.; Deng, H.; Jiang, H. Silver-catalyzed decarboxylative radical allylation of α,α-difluoroarylacetic acids for the construction of CF2-allyl bonds. Org. Biomol. Chem. 2021, 19, 2023–2029. [Google Scholar] [CrossRef]
  38. Liu, X.; Wang, Z.; Cheng, X.; Li, C. Silver-Catalyzed decarboxylative alkynylation of aliphatic carboxylic acids in aqueous solution. J. Am. Chem. Soc. 2012, 134, 14330–14333. [Google Scholar] [CrossRef] [PubMed]
  39. Hu, F.; Shao, X.; Zhu, D.; Lu, L.; Shen, Q. Silver-Catalyzed decarboxylative trifluoromethylthiolation of aliphatic carboxylic acids in aqueous emulsion. Angew. Chem. Int. Ed. 2014, 53, 6105–6109. [Google Scholar] [CrossRef]
  40. Zhu, Y.; Li, X.; Wang, X.; Huang, X.; Shen, T.; Zhang, Y.; Sun, X.; Zou, M.; Song, S.; Jiao, N. Silver-Catalyzed decarboxylative azidation of aliphatic carboxylic acids. Org. Lett. 2015, 17, 4702–4705. [Google Scholar] [CrossRef]
  41. Du, P.; Sun, Q.; Li, H.; Zhang, J.; Deng, H.; Jiang, H. Silver-catalyzed radical cascade arylthiodifluoromethylation/cyclization of isonitriles for the synthesis of 6-phenanthridinyldifluoromethyl aryl thioethers. Chem. Asian J. 2022, 17, e202200088. [Google Scholar] [CrossRef] [PubMed]
  42. Hu, H.; Chen, X.; Sun, K.; Wang, J.; Liu, Y.; Liu, H.; Yu, B.; Sun, Y.; Qu, L.; Zhao, Y. Silver-catalyzed decarboxylative cascade radical cyclization of tert-carboxylic acids and o-(allyloxy)arylaldehydes towards chroman-4-one derivatives. Org. Chem. Front. 2018, 5, 2925–2929. [Google Scholar] [CrossRef]
  43. Cui, L.; Chen, H.; Liu, C.; Li, C. Silver-Catalyzed decarboxylative allylation of aliphatic carboxylic acids in aqueous solution. Org. Lett. 2016, 18, 2188–2191. [Google Scholar] [CrossRef] [PubMed]
  44. Jagdale, A.R.; Park, J.H.; Youn, S.W. Cyclization Reaction for the Synthesis of Polysubstituted Naphthalenes in the Presence of Au (I) Precatalysts. J. Org. Chem. 2011, 76, 7204–7215. [Google Scholar] [CrossRef]
  45. Mizuta, S.; Stenhagen, I.S.R.; O’Duill, M.; Wolstenhulme, J.; Kirjavainen, A.K.; Forsback, S.J.; Tredwell, M.; Sandford, G.; Moore, P.R.; Huiban, M.; et al. Catalytic decarboxylative fluorination for the synthesis of tri-and difluoromethyl arenes. Org. Lett. 2013, 15, 2648–2651. [Google Scholar] [CrossRef]
  46. Chang, Y.; Tewari, A.; Adi, A.; Bae, C. Direct nucleophilic fluorination of carbonyl groups of benzophenones and benzils with Deoxofluor. Tetrahedron 2008, 64, 9837–9842. [Google Scholar] [CrossRef]
Molecules 28 03578 g001 550
Figure 1. Examples of the bioactive compounds with a 3-substituent chroman-4-one moiety.
Figure 1. Examples of the bioactive compounds with a 3-substituent chroman-4-one moiety.
Molecules 28 03578 g001
Molecules 28 03578 sch001 550
Scheme 1. Synthesis of 3-difluoromethylene-containing chroman-4-one derivatives.
Scheme 1. Synthesis of 3-difluoromethylene-containing chroman-4-one derivatives.
Molecules 28 03578 sch001
Molecules 28 03578 g002 550
Figure 2. X-ray crystallography of 3aq′ (gray for carbon atoms, green for fluorine atom, yellow for sulfur atom and red for oxygen atom).
Figure 2. X-ray crystallography of 3aq′ (gray for carbon atoms, green for fluorine atom, yellow for sulfur atom and red for oxygen atom).
Molecules 28 03578 g002
Molecules 28 03578 sch002 550
Scheme 2. Control experiments.
Scheme 2. Control experiments.
Molecules 28 03578 sch002
Molecules 28 03578 sch003 550
Scheme 3. Plausible reaction mechanism.
Scheme 3. Plausible reaction mechanism.
Molecules 28 03578 sch003
Table
Table 1. Optimization of Reaction Conditions a.
Table 1. Optimization of Reaction Conditions a.
Molecules 28 03578 i001
EntryCatalyst (mol%)Oxidant (equiv.)SolventYield (%) b
1AgNO3 (20)K2S2O8 (2.0)CH3CN/H2O (1:1)56
2AgNO3 (20)K2S2O8 (2.0)DMSO/H2O (1:1)45
3AgNO3 (20)K2S2O8 (2.0)EtOH/H2O (1:1)5
4AgNO3 (20)K2S2O8 (2.0)H2O10
5AgNO3 (20)K2S2O8 (2.0)CH3CNN.R.
6AgNO3 (20)K2S2O8 (2.0)CH3CN/H2O (1:3)73
7AgNO3 (20)Na2S2O8 (2.0)CH3CN/H2O (1:3)66
8AgNO3 (20)(NH4)2S2O8 (2.0)CH3CN/H2O (1:3)63
9AgNO3 (20)Selectfluor (2.0)CH3CN/H2O (1:3)0
10\K2S2O8 (2.0)CH3CN/H2O (1:3)49
11AgNO3 (20)\CH3CN/H2O (1:3)0
12AgNO3 (30)K2S2O8 (2.0)CH3CN/H2O (1:3)67
13AgNO3 (10)K2S2O8 (2.0)CH3CN/H2O (1:3)63
14 cAgNO3 (20)K2S2O8 (2.0)CH3CN/H2O (1:3)50
15 dAgNO3 (20)K2S2O8 (2.0)CH3CN/H2O (1:3)53
16 eAgNO3 (20)K2S2O8 (2.0)CH3CN/H2O (1:3)68
17AgNO3 (20)K2S2O8 (1.75)CH3CN/H2O (1:3)70
18AgNO3 (20)K2S2O8 (2.25)CH3CN/H2O (1:3)64
19AgOAc (20)K2S2O8 (2.0)CH3CN/H2O (1:3)65
20Ag2O (20)K2S2O8 (2.0)CH3CN/H2O (1:3)68
21Ag2CO3 (20)K2S2O8 (2.0)CH3CN/H2O (1:3)65
22 f\(NH4)2S2O8 (2.0)DMSO32
a Reaction conditions: 1a (0.2 mmol, 1.0 equiv.), 2a (0.3 mmol, 1.5 equiv), catalyst (20 mol%) and oxidant (0.4 mmol) in 2.0 mL solvent at 80 °C for 4 h under N2 atmosphere. b Yields determined by 19F NMR analysis with PhCF3 as the internal standard. c 1a:2a = 1:1. d 1a:2a = 1.5:1. e 1a:2a = 1:2. f 1a (0.2 mmol), 2 (0.3 mmol), (NH4)2S2O8 (0.4mmol) and DMSO (2.0 mL) at 40 °C for 6 h under N2 atmosphere.
Table
Table 2. Scope of α,α-difluoroarylacetic acids a,b.
Table 2. Scope of α,α-difluoroarylacetic acids a,b.
Molecules 28 03578 i002
Molecules 28 03578 i003
a Reaction conditions: 1a (0.2 mmol), 2a (0.3 mmol), AgNO3 (20 mol%) and K2S2O8 (0.4 mmol) in 2.0 mL CH3CN/H2O (v/v = 1:3) solution at 80 °C for 4 h under N2 atmosphere. b Isolated yields.
Table
Table 3. Scope of 2-allyloxybenzaldehydes a,b.
Table 3. Scope of 2-allyloxybenzaldehydes a,b.
Molecules 28 03578 i004
Molecules 28 03578 i005
a Reaction conditions: 1a (0.2 mmol), 2 (0.3 mmol), AgNO3 (20 mol%) and K2S2O8 (0.4 mmol) in 2.0 mL CH3CN:H2O = 1:3 solution at 80 °C for 4 h under N2 atmosphere. b Isolated yields. c 1a (0.2 mmol), 2 (0.3 mmol), (NH4)2S2O8 (0.4mmol) in 2.0 mL DMSO at 40 °C for 6 h under N2 atmosphere.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sun, Q.; Li, H.; Chen, X.; Hao, J.; Deng, H.; Jiang, H. Silver-Promoted Radical Cascade Aryldifluoromethylation/Cyclization of 2-Allyloxybenzaldehydes for the Synthesis of 3-Aryldifluoromethyl-Containing Chroman-4-one Derivatives. Molecules 2023, 28, 3578. https://doi.org/10.3390/molecules28083578

AMA Style

Sun Q, Li H, Chen X, Hao J, Deng H, Jiang H. Silver-Promoted Radical Cascade Aryldifluoromethylation/Cyclization of 2-Allyloxybenzaldehydes for the Synthesis of 3-Aryldifluoromethyl-Containing Chroman-4-one Derivatives. Molecules. 2023; 28(8):3578. https://doi.org/10.3390/molecules28083578

Chicago/Turabian Style

Sun, Qianqian, Hongxiao Li, Xingyu Chen, Jian Hao, Hongmei Deng, and Haizhen Jiang. 2023. "Silver-Promoted Radical Cascade Aryldifluoromethylation/Cyclization of 2-Allyloxybenzaldehydes for the Synthesis of 3-Aryldifluoromethyl-Containing Chroman-4-one Derivatives" Molecules 28, no. 8: 3578. https://doi.org/10.3390/molecules28083578

Article Metrics

Back to TopTop